Inhibition of Jurkat T Cell Growth by N-farnesyl-norcantharimide Through Up-regulation of Tumor Suppressor Genes and Down-regulation of Genes for Steroid Biosynthesis, Metabolic Pathways and Fatty Acid Metabolism.
Anticancer Res
; 40(5): 2675-2685, 2020 May.
Article
em En
| MEDLINE
| ID: mdl-32366412
ABSTRACT
BACKGROUND/AIM:
To evaluate the anti-cancer mechanism of N-Farnesyl-norcantharimide (NC15). MATERIALS ANDMETHODS:
The viability of NC15-treated human leukemic Jurkat T (JKT) cells was assessed using the Kit-8 cell counting method. Flow cytometry analysis, human apoptosis antibody array assay, and whole genome sequencing were adopted to investigate the mechanism underlying the anti-cancer activity of NC15 in JKT cells.RESULTS:
The growth inhibition rates of NC15 in JKT cells were about 80% and 95% after treatment with 8 µmol/l NC15 for 24 and 48 h, respectively. The percentages of NC15-treated JKT cells in the sub-G1 phase at 24 and 48 h were 22.0% and 34.3%, respectively, in contrast to the 1.5% in the control. Next-generation sequencing showed that many tumor suppressor genes (TSG) were up-regulated, while many genes associated with steroid biosynthesis, metabolic pathways, and fatty acid metabolism were down-regulated.CONCLUSION:
NC15 can reduce the cell viability and increase the percentage of JKT cells in the sub-G1 phase by up-regulating TSG and related genes, and down-regulating the genes for steroid biosynthesis, metabolic pathways and fatty acid metabolism, instead of through apoptosis.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esteroides
/
Cantaridina
/
Linfócitos T
/
Regulação para Baixo
/
Regulação para Cima
/
Genes Supressores de Tumor
/
Redes e Vias Metabólicas
/
Ácidos Graxos
Limite:
Humans
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2020
Tipo de documento:
Article